A hidden army of gut microbes can brew alcohol inside the body—and scientists may finally know how to stop it.

BioArctic AB's (publ) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of Leqembi (lecanemab) for ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

A1C, LDL, HDL… the number of medical abbreviations you might see on your patient portal is enough to make you think your ...

Overall, it found that patients could lose up to a fifth of their body weight using the injectable GLP-1s, but put it back on at a rate of 0.8 kg a month after the treatment stopped, which means that ...

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune ...

For most healthy women, optimal fasting insulin levels should be less than 25 mIU/L (milli-international units per liter), ...

Topline data were announced from the phase 3 INDIGO trial evaluating obexelimab in adults with immunoglobulin G4-related disease.

Cleveland Clinic researchers have discovered that bacteria inside cancerous tumors may be key to understanding why ...

As people with α-gal syndrome seek to boost awareness, researchers are looking to harness the molecule for new therapies ...